Increased infection risk in patients on preventive CGRP-targeting therapies– a meta-analysis and clinical effect assessment
Abstract Background Calcitonin gene related peptide (CGRP) pathway targeting therapies have proven efficacy, safety and tolerability. However, CGRP is also involved in immune responses, and reports of an increased risk of infection have emerged. This meta-analysis aims to verify whether CGRP-targeti...
Saved in:
| Main Authors: | Marcin Straburzyński, Daria Kopyt, Karol Marschollek, Bartłomiej Błaszczyk, Ewa Kuca-Warnawin, Weronika Kurowska, Błażej Misiak, Kuan-Po Peng, Marta Waliszewska-Prosół, Arne May |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | The Journal of Headache and Pain |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s10194-025-02040-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A National Cross-Sectional Survey on Real-World Experiences of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody Use in Adults with Migraine in Finland
by: Caroline S. Casey, et al.
Published: (2025-04-01) -
Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)
by: Davor Jančuljak, et al.
Published: (2024-01-01) -
Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache - a retrospective real-world analysis
by: Armin Scheffler, et al.
Published: (2024-07-01) -
In the era of monoclonal antibodies targeting the calcitonin gene-related peptide pathway, is it still necessary to stop taking excessive pain medication?
by: Renata Gomes Londero
Published: (2025-09-01) -
A retrospective analysis of migraine prophylaxis with anti-CGRP monoclonal antibodies at the hospital of Lithuanian University of Health Sciences Kaunas Clinics
by: V. Karpavičiūtė, et al.
Published: (2023-10-01)